Krystal Biotech (KRYS) Total Non-Current Liabilities (2018 - 2026)

Krystal Biotech (KRYS) has 5 years of Total Non-Current Liabilities data on file, last reported at $115.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 31.22% year-over-year to $115.1 million; the trailing twelve-month figure through Mar 2026 stood at $115.1 million (up 31.22% YoY), and the FY2025 full-year result was $110.5 million, up 2.29% from the prior year.
• Total Non-Current Liabilities improved to $115.1 million in Q1 2026, from $110.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $115.1 million in Q1 2026 to a low of $39.7 million in Q4 2023.
• A 4-year average of $92.1 million and a median of $95.7 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities jumped 172.04% in 2024 and advanced 2.29% in 2025, its largest moves.
• Tracing KRYS's Total Non-Current Liabilities over 4 years: stood at $39.7 million in 2023, then jumped by 172.04% to $108.0 million in 2024, then increased by 2.29% to $110.5 million in 2025, then gained by 4.19% to $115.1 million in 2026.
• Business Quant data shows KRYS's Total Non-Current Liabilities at $115.1 million in Q1 2026, $110.5 million in Q4 2025, and $99.1 million in Q3 2025.